Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 30, 2023
|
| In: |
Translational Lung Cancer Research
Year: 2023, Jahrgang: 12, Heft: 11, Pages: 2322-2329 |
| ISSN: | 2226-4477 |
| DOI: | 10.21037/tlcr-23-487 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.21037/tlcr-23-487 Verlag, kostenfrei, Volltext: https://tlcr.amegroups.org/article/view/80018 |
| Verfasserangaben: | Bowen Li, Ziqi Jia, Zhicheng Huang, Jianchao Xue, Yadong Wang, Chao Guo, Xiaoyan Si, Zexin Chen, Ji Li, Rongrong Chen, Zhixin Bie, Andrea De Giglio, Petros Christopoulos, Naixin Liang, Shanqing Li |
| Zusammenfassung: | Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report |
|---|---|
| Beschreibung: | Gesehen am 08.12.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 2226-4477 |
| DOI: | 10.21037/tlcr-23-487 |